GSK PLC-SPON ADR (GSK) Institutional Buying Activity
Institutional investors tracked by InsiderSet increased exposure to GSK PLC-SPON ADR (GSK) during the quarter ended March 31, 2026 through a combination of new purchases and expanded existing positions disclosed in SEC Form 13F filings.
The largest institutional buyer of GSK during the latest reporting period was Hancock Classic Value, which increased its reported GSK position by approximately $296,865.475 based on quarter-end filing values. Several additional hedge funds and long-term asset managers also reported meaningful increases in GSK exposure during the quarter.
Institutional buying activity can provide insight into investor conviction, sector allocation trends, and smart money positioning toward GSK PLC-SPON ADR (GSK). InsiderSet tracks quarterly accumulation trends, new institutional positions, ownership increases, and estimated performance of newly disclosed holdings using SEC filing data and recent market prices.
The investors highlighted on this page collectively added approximately $398,800.842 in reported GSK exposure during the latest filing period, reflecting continued institutional interest in GSK PLC-SPON ADR's growth initiatives and strategic positioning.
| Portfolio quarter | Name | Type | Quantity | Remaining | Reported stock balance |
|---|---|---|---|---|---|
| Q1 2026 | Hancock Classic Value | Buy | 5,379 | 18,823 | $1,038,836 |
| Q1 2026 | Sequoia Financial Advisors | Buy | 1,847 | 35,652 | $1,967,623 |
Frequently asked questions about GSK activity
Which institutional owners are buying GSK?
Institutional owners buying GSK include investors who have either initiated new positions or increased their existing holdings based on recent SEC 13F filings. The activity table above highlights which funds added shares in the latest reporting periods and how their positions changed over time.
What does "buy" mean in GSK activity?
"Buy" means an investor increased their reported position in GSK compared to the prior reporting period. This reflects growing exposure to GSK PLC-SPON ADR (GSK) rather than necessarily a brand-new position (though new positions also appear as buys when prior quantity was zero).
Is institutional interest in GSK increasing?
Institutional interest in GSK can be assessed by comparing the number of tracked funds adding or increasing positions versus those trimming or exiting across the periods shown. A higher number of additions typically signals increasing participation among large filers, but it should be read alongside position sizes and the full table.